Latest Breaking News On - மூளை ஆற்றல் - Page 1 : comparemela.com

  T3D Therapeutics, Inc.: T3D Therapeutics Announces First Patient Dosed in its Phase 2 Study of T3D-959 for the Treatment of Mild to Moderate Alzheimer s Disease Research Triangle Park, 04/20/2021 EQS Newswire - T3D Therapeutics, Inc.   RESEARCH TRIANGLE PARK, NC / ACCESSWIRE / April 20, 2021 / T3D Therapeutics, Inc. ( T3D ), a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer s disease (AD), announced today the initiation of dosing in a Phase 2 clinical study of neurometabolic regulator T3D-959 in patients with mild to moderate Alzheimer s disease, the PIONEER Study. T3D-959 is a small molecule, orally-delivered, brain-penetrating PPAR delta/gamma dual nuclear receptor agonist designed to improve both glucose and lipid metabolism dysfunctions present in AD, and other neurodegenerative disorders.

Roberta diaz brintonJohn didsburyWarren strittmatterFd therapeutics incNational institutes of healthNational institute onAlzheimer association zenith awardResearch triangle parkTherapeutics announces first patient dosedModerate alzheimerTriangle parkChief medical officerEmeritus professorDuke university medical centerAssociation zenith awardScientific advisory board